EUCTR2020-005173-28-AT进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis - HARBOR
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 463
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All Patients
- •1. Patient must be = 16 years of age at the time of signing the informed consent/assent. (In France, Sweden, Germany, and Spain, only patients
- •who are = 18 years of age are allowed).
- •2. Patient must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2.
- •With ISM in Part 1 and Part 2
- •3. Patient must have moderate-to-severe symptoms based on minimum mean total symptom score (TSS) of the ISM Symptom Assessment Form
- •(ISM-SAF) over the 14-day eligibility screening period.
- •With ISM in Part 1, Part 2 and PK groups
- •4. Patient has confirmed diagnosis of ISM, confirmed by Central Pathology Review of BM biopsy and central review of B- and C-findings
- •by WHO diagnostic criteria. Archival biopsy may be used if completed within the past 12 months.
- •5. Patient must have failed to achieve adequate symptom control for 1 or more Baseline symptoms, as determined by the Investigator, with at
- •least 2 of the following symptomatic therapies administered: H1 blockers, H2 blockers, proton-pump inhibitors, leukotriene inhibitors, cromolyn sodium, corticosteroids, or omalizumab.
- •6. Patients must have BSC for ISM symptom management stabilized for at least 14 days prior to starting screening procedures.
- •7. For patients receiving corticosteroids, the dose must be = 20 mg/d prednisone or equivalent, and the dose must be stable for = 14 days.
- •With mMCAS in Part M
- •8. Patients must have mMCAS, confirmed by Central Pathology Review of BM biopsy. An archival biopsy may be used if completed within the past
- •9. Patients must have tryptase < 20 ng/mL.
- •10. Patients must have KIT D816V in PB or BM and/or CD25+ Mast cells in BM.
- •11. Patients must have symptoms consistent with mast cell activation (despite BSC) in at least two organ systems characterized by cutaneous
- •flushing, tachycardia, syncope, hypotension, diarrhea, nausea, vomiting and GI cramping and sBT levels above 8 ng/mL OR Severe (Ring and
- •Messmer grading = II), recurrent anaphylaxis, including but not limited to hymenoptera venom, drug or food, regardless of sBT levels.
- •With ISM in PK Groups
- •12. Accrual may be limited to patients who have specific disease manifestations (ie, GI involvement) or are taking acid-reducing agents to better explore the impact of these features on PK.
- •With SSM in Part S:
- •13.Patient has confirmed diagnosis of SSM, confirmed by Central Pathology Review of BM biopsy and central review of B- and C-findings by WHO 2022 diagnostic criteria . No archival BM biopsies will be accepted without approval from the Sponsor.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 3
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 435
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •Key Exclusion Criteria:
- •1. Patient has been diagnosed with any of the following WHO SM subclassifications: cutaneous mastocytosis only, SM-AHN, ASM, MCL, Mast cell sarcoma.
- •2. Patient has been diagnosed with another myeloproliferative disorder.
- •3. Patient has organ damage C-findings attributable to SM.
- •4. Patient has a QT interval corrected using Fridericia's formula (QTcF) > 470 msec (for females) or > 450 msec (for males).
- •5. Patient has clinically significant, uncontrolled, cardiovascular disease.
- •6. Patient has previously received treatment with any selective KIT inhibitors (avapritinib, bezuclastinib, and ripretinib).
- •7. Patient has a history of a primary malignancy that has been diagnosed or required therapy within 3 years. The following prior malignancies are not exclusionary: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site.
- •8. Time since any cytoreductive therapy including mastinib and midostaurin should be at least 5 half-lives or 14 days (whichever is longer), and for cladribine, interferon alpha, pegylated interferon, or antibody therapy < 28 days or 5 half-lives of the drug (whichever is longer), before beginning the screening period.
- •9. Patient has received radiotherapy or PUVA therapy < 14 days before beginning the screening period.
- •10. Patient has known active SARS-CoV-2infection (Germany Only).
- •11. Patients not eligible for an MRI due to contraindications (eg, patients with implanted defibrillators or other metallic devices not approved for MRI [Germany only]).
研究者
相似试验
进行中（未招募）
1 期
A Study of Efficacy and Safety of M2951 in Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-001448-21-BGMerck KGaA250
进行中（未招募）
1 期
Vedolizumab IV 300 mg in the Treatment of Chronic PouchitisChronic PouchitisMedDRA version: 20.0Level: PTClassification code 10036463Term: PouchitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2015-003472-78-ITTAKEDA DEVELOPMENT CENTRE EUROPE LTD102
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy.C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN).MedDRA version: 20.0Level: PTClassification code 10077827Term: C3 glomerulopathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2017-001821-42-ITChemoCentryx, Inc.44
进行中（未招募）
1 期
A Study of BLU-263 in patients with Indolent Systemic MastocytosisIndolent Systemic Mastocytosis (ISM) and monoclonal Mast Cell Activation Syndrome (mMCAS)MedDRA version: 27.0Level: PTClassification code 10056452Term: Indolent systemic mastocytosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005173-28-BEBlueprint Medicines Corporation463
进行中（未招募）
1 期
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)Metastatic gastric adenocarcinoma or gastroesophageal junction (GEJ) denocarcinomaMedDRA version: 20.0Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002240-40-CZEli Lilly and Company616